Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here are the FACTS according to the SEC.
——————————————— 2016 ———————————————
"31. On January 21, 2016, Friedland and his company Global entered into a two-year “Media, Public Relations and Investor Relations Services Agreement” with OWC (hereinafter, the “Global PR/IR Agreement”), which Friedland signed as Managing Director of Global. Under the terms of the Global PR/IR Agreement, Friedland agreed to develop a media, public relations, and investor relations program to create interest in OWC on the part of financial journalists, institutional investors, and the general investment community. In this role, Friedland agreed to “create a higher level awareness of [OWC], as well as the anticipated impact with the investors[;] [Global] will provide both an introduction of the company to the overall American population, as well as specifically target investors.” The agreement also states that Global would assist OWC in reaching investors by writing news releases, shareholder letters, corporate summaries, profiles, and website copy, and would establish OWC’s Facebook and Twitter accounts. The Global PR/IR Agreement stated that it could only be amended if executed by the parties in writing.
32. Pursuant to the compensation terms of the Global PR/IR Agreement, OWC transferred 5,134,375 OWC shares to Global on February 5, 2016. OWC provided an attorney opinion letter to OWC’s transfer agent from a disbarred attorney in connection with the issuance of OWC’s stock to Global. OWC disclosed in reports it filed with the SEC in February 2016 that Global owned these shares of stock – 6.3% of OWC’s common stock at that time – and that Friedland controlled them as Global’s President and CEO, but neither OWC, Friedland, nor Global made any disclosure as to how the shares were acquired by Global."
There was nothing fraudulent about OWC entering into a 2-year “Media, Public Relations and Investor Relations Services Agreement” with Friedland and his company Global and they paid him according to the agreement a reasonable amount of 5,134,375 OWC shares to Global. On January 21, 2016 the PPS of OWCP stock was .04 to .08 and therefore 5,134,375 shares would have been worth $205,375 at .04. It’s fair to say that if someone had done a PP with OWCP during that same time period, they could have gotten a PPS of .04 or less.
This has been discussed before [with you]. What you are saying in your post is intentional deception. Why are you trying to deceive people?
Good post!
$OWCP
You're WRONG! It's obvious you have no idea what patents are. Not all patents are one in the same. Different companies have different patents, it's just a fact. Also, a single company can have more than just one patent. This is just a fact as well. OWCP has 31 patents registered in 9 patent families.
The post you are replying to is solely about the OWCP patent pending for "CANNABIS-BASED EXTRACTS AND TOPICAL FORMULATIONS FOR USE IN SKIN DISORDERS".
The OWCP patent pending for:
CANNABIS-BASED EXTRACTS AND TOPICAL FORMULATIONS FOR USE IN SKIN DISORDERS
- Is NOT the same patent as -
The OWCP patent pending for:
USE OF CANNABIS TO TREAT FIBROMYALGIA, METHODS AND COMPOSITIONS THEREOF
Here is a link to the OWCP patent application for "CANNABIS-BASED EXTRACTS AND TOPICAL FORMULATIONS FOR USE IN SKIN DISORDERS" updated Feb. 15, 2018. The science very impressive and extensive. In revising THIS patent application, OWCP did NOT cancel Claims 1-87.
https://patentimages.storage.googleapis.com/b8/1c/09/45c55ac2ed6c11/US20180042890A1.pdf
As for the OWCP patent pending for "USE OF CANNABIS TO TREAT FIBROMYALGIA, METHODS AND COMPOSITIONS THEREOF" updated May 3, 2018. Let's take a look at the science, which is very impressive and extensive.
It's is amazing! A lot of time was spent to record the dosages, effects, and the patients' reactions to various form of deliveries.
Relieving from Fibromyalgia syndrome symptoms!
1-87. cancelled
88. A composition comprising a therapeutically effective amount of Tetrahydrocannabinol (THC) or a derivative thereof, or Cannabidiol (CBD) or a derivative thereof, or a combination thereof for use in relieving a subject suffering from fibromyalgia syndrome symptoms.
89. The composition of claim 88, wherein at least one of the following holds true: a) said Tetrahydrocannabinol (THC) or a derivative thereof, or said Cannabidiol (CBD) or a derivative thereof is from cannabis extract; b) said THC a derivative thereof is selected from the group consisting of THC, Tetrahydrocannabivarin (THCV), Tetrahydrocannabinolic acid (THCA) and any combination thereof; c) said THC or a derivative thereof is selected from the group consisting of natural THC or a derivative thereof produced in the body of humans and animals, THC or a derivative thereof extracted from plants, synthetic THC or a derivative thereof, and any combination thereof; d) said THC or a derivative thereof is extracted from cannabis; said cannabis is selected from the group comprising of: Cannabis sativa, Cannabis indica, Cannabis ruderalis, and any combination thereof; e) said cannabidiol (CBD) or a derivative thereof is selected from the group consisting of CBD, cannabidivarin (CBDV), cannabidiolic acid (CBDA) and any combination thereof; f) said CBD or a derivative thereof is selected from the group consisting of natural CBD or a derivative thereof produced in the body of humans and animals, CBD or a derivative thereof extracted from plants, synthetic CBD or a derivative thereof, and any combination thereof; g) said CBD or a derivative thereof is extracted from cannabis; said cannabis is selected from a group consisting of: Cannabis sativa, Cannabis indica, Cannabis ruderalis, and any combination thereof; h) the concentration of said THC is in the range of about 2% to about 85%; and i) the concentration of said CBD is in the range of about 2% to about 85%.
90. The composition of claim 88, further comprising a ratio of said THC, or a derivative thereof, to said CBD, or a derivative thereof of 4:1 or 5:1, respectively.
91. The composition of claim 88, wherein said composition is formulated for administration of at least one of: a) between about 10 mg THC and about 160 mg THC per day, preferably between about 10 mg and about 100 mg THC per day; b) between about 5 mg THC and about 20 mg THC per dosage unit, preferably about 10 mg THC per dosage unit; c) between about 2 mg CBD and about 40 mg CBD per day, preferably between about 2 mg and about 20 mg CBD per day; d) between about 1 mg CBD and about 5 mg CBD per dosage unit, preferably about 2 mg CBD per dosage unit; and e) about 1 to about 10 times per day.
92. The composition of claim 88, wherein at least one of the following holds true: a) said composition is administered in a manner selected from the group consisting of: intranasal, transdermal, topical, intravenous, oral, and any combination thereof; b) said composition is formulated in the form of drops; c) said composition is formulated in a dosage form selected from the group consisting of oil, liquid, solid, gas, oral, pill, tablet, capsule, buccal, sub-lingual, orally-disintegrating, thin film, liquid solution, suspension, powder or liquid or solid crystals, pastes, inhalational, aerosol, inhaler, nebulizer, smoking, vaporizer, parenteral, intradermal, intramuscular, intraosseous, intraperitoneal, intravenous, subcutaneous, topical, cream, gel, liniment or balm, lotion, ointment, drops, skin patch, vaginal, suppository, pessary, rectal and any combination thereof; and d) said composition is administered in combination with at least one therapeutic agent selected from the group comprising of dypirone, pregabalin, duloxetine, milnacipran, tricyclic antidepressants, amitriptyline, gabapentin, paracetamol, tramadol, codeine, growth hormone, sodium oxybate, cyclobenzaprine, tizanidine, pramipexole, ropinirole, quercetin and any combination thereof.
93. The composition according to claim 92, wherein said composition provides a synergistic effect with respect to treatment of fibromyalgia when administered in combination with said therapeutic agent, as compared to the effect provided when said composition and said therapeutic agent administered separately.
94. The composition of claim 88, wherein at least one of the following holds true: a) said composition additionally comprises at least one carrier or excipient selected from the group consisting of diluents, antiadherents, binders, coatings, disintegrants, surfactants, dissolving agents, solubilising agents, bioadhesive agents, polysaccharides, polymers, copolymers, fast dissolving tablet (FDT) type excipient, bioavailability enhancing agent, Thin Film type excipient, PharmFilm type excipient, mucoadhesive type excipient, acidifying agents, probiotic agents, protective agents, antioxidants, effervescent excipient, dispersing agents flavours, colours, lubricants, glidants, sorbents, preservatives, sweeteners, and any combination thereof; b) said composition further comprising flavoring agents, selected from the group consisting of sugar, sucrose, sorbitol, sucralose, saccharin sodium, sodium cyclamate, aspartame, neotame, acesulfame potassium, stevioside, sodium chloride, D-limonene, citric acid and any combination thereof; c) said composition further comprising preservatives, selected from the group consisting of methylparabens, ethylparabens, propylparabens, butylparabens, sorbic acid, acetic acid, propionic acid, sulfites, nitrites, sodium sorbate, potassium sorbate, calcium sorbate, benzoic acid, sodium benzonate, potassium benzonate, calcium benzonate, sodium metabisulfite, propylene glycol, benzaldehyde, butylated hydroxytoluene, butylated hydroxyanisole, formaldehyde donors, essential oils, monoglyceride, phenol, mercury components and any combination thereof; d) said composition is in a sustained release dosage form or in an immediate release dosage form; and e) said composition is in a sustained release dosage form selected from the group comprising of liposomes, drug polymer conjugates, microencapsulation, controlled-release tablet coating, and any combination thereof.
95. The composition of claim 88, wherein said composition is used for preventing the onset of a flareup of fibromyalgia symptoms in said subject.
96. The composition of claim 88, wherein said composition provides an improvement in fibromyalgia symptoms of said subject as measured by at least one pain severity scale, compared to an established baseline, control or placebo.
97. The composition of claim 96, wherein at least one of the following holds true: a) said improvement in fibromyalgia symptoms is measured by an improvement in the subject's score of at least one point on said at least one pain severity scale, as compared to an established baseline or to a placebo; b) said at least one pain severity scale is selected from the group comprising of Brief pain inventory (BPI), Sleep history questionnaire (PSQI), SF-36 Quality of life assessment, Fibromyalgia impact questionnaire (FIQ), Mini International Neuropsychiatric Interview, Hamilton Anxiety Rating Scale (HAM-A) and Hamilton Rating Scale for Depression (HRSD), fibromyalgia syndrome Tenderness Assessment, Hamilton Depression Rating Scale (HORS) and any combination thereof; c) said fibromyalgia symptoms are selected from the group comprising of widespread pain, chronic pain, cognitive difficulties, chronic muscle pain, muscle spasms, muscle tightness, fatigue, insomnia, stiffness, fibro fog, abdominal pain, bloating, nausea, constipation, diarrhea, headache, jaw and facial tenderness, anxiety, depression, numbness or tingling in the limbs, irritable bladder, feeling of swelling, painful menstruation, restless leg, dizziness, female or subject with established FMS confirmed by the 1990 ACR and any combination thereof; and d) a sensitivity to at least one of the following: odors, noise, bright lights, medications, certain foods, and cold.
98. The composition of claim 97, wherein said composition provides at least one of: a) an improvement in fibromyalgia symptoms of said subject measured by a score on the average pain severity item of the BPI scale of above 5; b) a reduction in BPI score from baseline to endpoint; and c) a sustained response defined as a 30% reduction from baseline to endpoint in the BPI score with a 30% reduction from baseline at least 2 weeks prior to the last, and with at least a 20% reduction from baseline at every week in between.
99. The composition of claim 88, wherein said composition provides at least one of: a) an improvement in pain severity as measured by the self-reported Brief Pain Inventory (short form) average pain severity score fibromyalgia impact questionnaire items; and b) improvement in measures selected from the group consisting of: quality of life, quality of sleep, disability, depression, anxiety and the patient global impression of change and the fibromyalgia severity score.
100. The composition of claim 99, Wherein said pain severity score fibromyalgia impact questionnaire items comprising items which measure physical function, pain assessment, fatigue and distress.
101. A method for treating a subject suffering from fibromyalgia syndrome comprising steps of administering to said subject a composition comprising a therapeutically effective amount of Tetrahydrocannabinol (THC) or a derivative thereof, or Cannabidiol (CBD) or a derivative thereof, or a combination thereof in a therapeutically effective dosage.
102. The method of claim 101, additionally comprising at least one step selected from the group consisting of: a) formulating said composition to comprise a ratio of said THC, or a derivative thereof, to said CBD, or a derivative thereof, of 4:1 or 5:1, respectively; b) administering said THC or a derivative thereof in a dosage unit of between about 5 mg THC and about 20 mg THC, preferably about 10 mg THC per dosage unit; c) administering said CBD or a derivative thereof in a dosage of between about 2 mg CBD and about 40 mg CBD per day, preferably between about 2 mg and about 20 mg CBD per day; d) administering said CBD or a derivative thereof in a dosage unit of between about 1 mg CBD and about 5 mg CBD, preferably about 2 mg CBD per dosage unit; e) formulating said composition in a dosage form of drops; f) preventing the onset of a fibromyalgia flareup in said subject; g) improving fibromyalgia symptoms of said subject as measured by at least one pain severity scale, compared to an established baseline, control or placebo; h) providing an improvement in fibromyalgia symptoms of said subject measured by a score on the average pain severity item of the BPI scale of above 5; i) providing a reduction in BPI score from baseline to endpoint; j) providing a sustained response defined as a 30% reduction from baseline to endpoint in the BPI score with a 30% reduction from baseline at least 2 weeks prior to the last, and with at least a 20% reduction from baseline at every week in between; and k) providing an improvement in pain severity as measured by the self-reported Brief Pain Inventory (short form) average pain severity score fibromyalgia impact questionnaire items.
103. The method of claim 102, wherein at least one of the following folds true: a) the method additionally comprising steps of performing blood tests for CBD and THC 1 hour and 2 hours after said dosage unit intake; b) the method additionally comprising steps of selecting said fibromyalgia symptoms to be a sensitivity to at least one of the following: odors, noise, bright lights, medications, certain foods, and cold; and c) said pain severity score fibromyalgia impact questionnaire items comprising items which measure physical function, pain assessment, fatigue and distress.
104. The method of claim 103, additionally comprising steps of providing improvement in measures selected from the group consisting of: quality of life, quality of sleep, disability, depression, anxiety and the patient global impression of change and the fibromyalgia severity score.
105. A composition comprising a therapeutically effective amount of cannabis formulation for use in relieving a subject suffering from fibromyalgia syndrome symptoms, wherein said cannabis formulation contains synthetic components of cannabis.
106. The composition of claim 105, wherein at least one of the following holds true: a) said synthetic components are synthetically produced tetrahydrocannabinol (THC) or a derivative thereof, or cannabidiol (CBD) or a derivative thereof, or a combination thereof; b) said composition comprising a ratio of said THC, or a derivative thereof, to said CBD, or a derivative thereof, of 4:1 or 5:1, respectively; c) said composition is formulated for administration of between about 10 mg THC and about 160 mg THC per day, preferably between about 10 mg and about 100 mg THC per day; and d) said composition is formulated for administration of about 2 mg CBD and about 40 mg CBD per day, preferably between about 2 mg CBD and about 20 mg CBD per day.
107. A method for preventing the risk for the onset of a fibromyalgia flareup, wherein said method comprises steps of: a) formulating a composition comprising tetrahydrocannabinol (THC) or a derivative thereof, or cannabidiol (CBD) or a derivative thereof, or a combination thereof; and b) administering said composition to a subject in risk for suffering from a fibromyalgia flareup according to a predetermined protocol.
108. The method of claim 107, wherein at least one of the following holds true: a) said step of formulating further comprises formulating said composition comprises a ratio of said THC, or a derivative thereof, to said CBD, or a derivative thereof, of 4:1 or 5:1, respectively; b) said method additionally comprising steps of administering said THC or a derivative thereof in a dosage of about 10 mg THC and about 160 mg THC per day, preferably between about 10 mg THC and about 100 mg THC per day per day; and c) said method additionally comprising steps of administering said CBD or a derivative thereof in a dosage of about 2 mg CBD and about 40 mg CBD per day, preferably between about 2 mg CBD and about 20 mg CBD per day.
$OWCP
There is no evidence that OWC colluded with Jeffery Friedland in 2014. Jeffery Friedland’s activities in Colorado were his activities, not those of OWC.
Your post reminds me of a previous false claim you made.
I-GLOW wrote:
“Yes, most certainly there was collusion and OWCP was complicit in the share selling scheme from beginning stating in 2014. The scam started at the Friedland dinner party in 2014.”
This statement of yours is no where in the SEC complaint document: “there was collusion and OWCP was complicit in the share selling scheme from beginning stating in 2014”, and does not merit a preface such as “Yes, most certainly”. The SEC action did not state this. It is not fact. It is not “most certainly”. The SEC complaint against Jeffery Friedlant actually exonerates OWC in my opinion, and they are not a party in this SEC action; fact.
There was no representative of OWC at Jeffery Friedland’s dinner party in Colorado in 2014. This was Jefferey Friedland doing his own thing in Colorado and the OWC management in Israel was not party to it.
According to the SEC, concerning OWC’s interaction with Jeffery Friedland in 2014, the FACTS ARE:
"29. In August 2014, Friedland purchased 1,322,222 shares of restricted OWC stock for $119,000 pursuant to a subscription agreement that he signed on behalf of Intiva, and the ownership of these securities was identified in OWC’s SEC filings (albeit with “Invita” rather than Intiva). On or around August 18, 2014, OWC provided an opinion letter to its transfer agent from a disbarred attorney in connection with its issuance of stock to Intiva."
There was nothing fraudulent about OWC issuing 1,322,222 shares of restricted OWC stock to Intiva in August 2014. Since there was nothing wrong with the issuance of these shares, there was nothing indicated as being fraudulent about the opinion letter which OWC provided to its transfer agent.
According to the SEC complaint against Friedland it says “from a disbarred attorney”, but we don’t know any additional information about the attorney OWC used in 2014. He/she may have had a current license to practice law at that time. Wether the attorney was disbarred prior to or after August 2014 is information not given by the SEC.
————————————————————————————————
Furthermore,
It is misleading to quote small bits out of the context of the actual SEC document; especially when you leave the year off, which was included in the document. The 3 different years of the 3 different 144 Opinion Letters as clearly stated in the SEC document is absolutely relevant. This SEC complaint exonerates OWCP.
Fact: The SEC did NOT state anywhere that OWC was party to any of Jeffery Friedland’s fraudulent activity, NOR Friedland’s fraudulent 144 Opinion Letter in January 2017.
Fact: The SEC stated that it was Friedland himself who provided the fraudulent 144 Opinion Letter to the transfer agent in January 2017.
Here is what the SEC document actually says about the 3rd opinion letter provided to the transfer agent in January 2017:
46. Friedland provided the transfer agent with a purported attorney opinion letter that included inaccurate information about Global’s acquisition of OWC stock and misleading information about the connection between Friedland, Global, and Lane 6552. The letter was signed by a disbarred attorney. "
Just so the FACTS are KNOWN AND CLEAR as the SEC has presented them; NOWHERE in the SEC complaint against Jeffery Friedland does it state that the two opinion letters provided by OWC in 2014 and 2016 are fraudulent. On the other hand, the SEC complaint does clearly state that the opinion letter provided by Jeffery Friedland in 2017 was fraudulent with this clear language used by the SEC in the SEC complaint (paragraph 46, page 14).
"Friedland provided the transfer agent with a purported attorney opinion letter that included inaccurate information about Global’s acquisition of OWC stock and misleading information about the connection between Friedland, Global, and Lane 6552."
The definition of purported is:
"appear or claim to be or do something, especially falsely; profess."
The SEC used very specific language as to why this opinion letter is fraudulent. This opinion letter was provided to the transfer agent in January 2017 by Jeffery Friedland (not OWC).
Since the SEC used the word purported, the opinion letter including the attorney's signature may have been forged. Either way, OWC is not implicated in any way regarding the 2017 opinion letter provided by Jeffery Friedland.
According to the SEC complaint against Friedland it says “from a disbarred attorney”, but we don’t know any additional information about the attorney OWC used in 2014 and 2016. He/she may have had a current license to practice law at that time. Wether the attorney was disbarred prior to or after August 2014 or February 5, 2016, is information not given by the SEC.
The FACTS have been presented by the SEC in their complaint against Jeffery Friedland, his wife, and their companies in Colorado. Those are the defendants in this case. OWC or OWCP are not implicated in the Friedland's fraudulent activity which started in January 2017.
The SEC complaint document does not state anywhere that Jeffery Friedland used the same attorney as OWC. Anytime I have worked with a lawyer, I have hired a lawyer somewhere near me. Friedland lives in Colorado and had 2 or more companies in Colorado between 2014 and 2017. It goes to reason that the lawyer(s) Friedland used in his affairs with his two Colorado companies is not the same lawyer used by OWC, a company located in Israel. Jeffery Friedland would have no problem finding lawyers in Colorado.
FACT: There are over 1.3 million attorneys in the United States.
As of 2016, there are 1,315,561 Licensed Lawyers in the United States of America.
http://www.denniswpottslaw.com/united-states-attorneys-map/
If Friedland's Attorney was disbarred as a result of the SEC’s investigation then it is most likely that he was disbarred in 2017 after having drafted and/or signed the third [fraudulent] opinion letter which Jeffery Freidland (not OWC) provided to the transfer agent. However, this information is not given by the SEC.
According to the SEC, here are THE FACTS ABOUT THE 3 DIFFERENT OPINION LETTERS TO THE OWC TRANSFER AGENT (years 2014, 2016, 2017)
——————————————— 2014 ———————————————
"29. In August 2014, Friedland purchased 1,322,222 shares of restricted OWC stock for $119,000 pursuant to a subscription agreement that he signed on behalf of Intiva, and the ownership of these securities was identified in OWC’s SEC filings (albeit with “Invita” rather than Intiva). On or around August 18, 2014, OWC provided an opinion letter to its transfer agent from a disbarred attorney in connection with its issuance of stock to Intiva."
There was nothing fraudulent about OWC issuing 1,322,222 shares of restricted OWC stock to Intiva in August 2014. Since there was nothing wrong with the issuance of these shares, there was nothing indicated as being fraudulent about the opinion letter which OWC provided to its transfer agent. According to the SEC complaint against Friedland it says “from a disbarred attorney”, but we don’t know any additional information about the attorney OWC used in 2014. He/she may have had a current license to practice law at that time. Wether the attorney was disbarred prior to or after August 2014 is information not given by the SEC.
——————————————— 2016 ———————————————
"31. On January 21, 2016, Friedland and his company Global entered into a two-year “Media, Public Relations and Investor Relations Services Agreement” with OWC (hereinafter, the “Global PR/IR Agreement”), which Friedland signed as Managing Director of Global.?Under the terms of the Global PR/IR Agreement, Friedland agreed to develop a media, public relations, and investor relations program to create interest in OWC on the part of financial journalists, institutional investors, and the general investment community. In this role, Friedland agreed to “create a higher level awareness of [OWC], as well as the anticipated impact with the investors[;] [Global] will provide both an introduction of the company to the overall American population, as well as specifically target investors.” The agreement also states that Global would assist OWC in reaching investors by writing news releases, shareholder letters, corporate summaries, profiles, and website copy, and would establish OWC’s Facebook and Twitter accounts. The Global PR/IR Agreement stated that it could only be amended if executed by the parties in writing.
32. Pursuant to the compensation terms of the Global PR/IR Agreement, OWC transferred 5,134,375 OWC shares to Global on February 5, 2016. OWC provided an attorney opinion letter to OWC’s transfer agent from a disbarred attorney in connection with the issuance of OWC’s stock to Global. OWC disclosed in reports it filed with the SEC in February 2016 that Global owned these shares of stock – 6.3% of OWC’s common stock at that time – and that Friedland controlled them as Global’s President and CEO, but neither OWC, Friedland, nor Global made any disclosure as to how the shares were acquired by Global."
There was nothing fraudulent about OWC entering into a 2-year “Media, Public Relations and Investor Relations Services Agreement” with Friedland and his company Global and they paid him according to the agreement a reasonable amount of 5,134,375 OWC shares to Global. On January 21, 2016 the PPS of OWCP stock was .04 to .08 and therefore 5,134,375 shares would have been worth $205,375 at .04. It’s fair to say that if someone had done a PP with OWCP during that same time period, they could have gotten a PPS of .04 or less.
Since there was nothing wrong with the issuance of these shares, there was nothing indicated as being fraudulent about the opinion letter which OWC provided to its transfer agent. According to the SEC complaint against Friedland it says “from a disbarred attorney”, but we don’t know any additional information about the attorney OWC used in 2016. He/she may have had a current license to practice law at that time. Wether the attorney was disbarred prior to or after February 5, 2016 is information not given by the SEC.
"36. On March 15, 2016, OWC issued a press release via PR Newswire announcing that Friedland had joined OWC’s Advisory Board to advise on business development efforts, and that Friedland would serve as the Company’s U.S. representative."
——————————————— 2017 ———————————————
"39. On or about January 3, 2017, Kathy Friedland organized Lane 6552 LLC, a company with no apparent business purpose or operations, with herself listed as the company’s sole member and principal.
43. On or about January 14, 2017, Friedland submitted a request to OWC’s transfer agent to reissue Global’s 5,134,375 shares of OWC stock to Lane 6552 LLC and remove the restricted legend from the securities.
45. In order to sell his restricted shares in the public marketplace, Friedland needed to have OWC’s transfer agent remove the restricted legend on Global’s 5,134,375 shares.
46. Friedland provided the transfer agent with a purported attorney opinion letter that included inaccurate information about Global’s acquisition of OWC stock and misleading information about the connection between Friedland, Global, and Lane 6552. The letter was signed by a disbarred attorney. "
According to the SEC, it was this 3rd opinion letter provided in January 2017 to OWC’s transfer agent that was fraudulent with “misleading information about the connection between Friedland, Global, and Lane 6552”. The SEC complaint is very clear that it was Jeffery Friedland who provided this 3rd fraudulent opinion letter (not OWC).
Since Jeffery Friedland was on OWC’s Advisory Board as announced in a PR by OWC about 10 months earlier on March 15, 2016, he may have used this leadership position with OWC which included his own OWC Email (Jfriedland@owcpharma.com), to have OWC’s transfer agent remove the restricted legend on Global’s 5,134,375 shares.
According to the SEC complaint against Friedland it says “from a disbarred attorney”, but we don’t know if the attorney who drafted and/or signed the opinion letter had a current license to practice law at that time or was disbarred prior to January 2017. The attorney may have been disbarred later, that information is not given by the SEC, but if the Attorney was disbarred as a result of the SEC’s investigation then it is most likely that he was disbarred in 2017 after having signed the 3rd opinion letter which Jeffery Freidland provided to the transfer agent.
According to the SEC, here is what fraudulent documents were provided to the transfer agent by Friedland (not OWC) in January 2017:
1. “46. Friedland provided the transfer agent with a purported attorney opinion letter that included inaccurate information about Global’s acquisition of OWC stock and misleading information about the connection between Friedland, Global, and Lane 6552. The letter was signed by a disbarred attorney.”
2. “48. Friedland also indicated on forms signed by his wife that were provided to the transfer agent that Global purchased the stock from OWC in January 2016 at a cost of $51,343.75, but there is no evidence of such payment from Global to OWC. The terms of Global’s agreement with OWC indicate the stock was compensation for media and investor relations services and not in exchange for any payment."
3. “49. Friedland further represented to the transfer agent on these forms that the OWC stock was not being transferred from Global to Lane 6552 as a gift, inheritance, or wash sale, but were instead acquired by Lane 6552 on January 13, 2017 at a cost of $205,375. There is no evidence of any payment to Global from Lane 6552 in that amount or on that date.”
"51. On February 3, 2017, OWC’s transfer agent, relying on the information provided by Friedland, removed the restrictive legend from Lane 6552’s stock."
————————————————————————————————
I-GLOW writes in previous post:
"What part about OWCP providing a Fraudulent Opinion Letter to expedite the removal of the restrictive legend are you ignoring."
Where does it say this in the SEC document? Paragraph and page please.
I'm still waiting...
Can you provide just the paragraph number please?
$OWCP
This is great news for OWCP. It shows that patents can be granted for Cannabis-Based products to treat a skin disorder.
OWCP has filed a patent application for extracts and topical formulations [such as skin cream], whereas CTT Pharmaceutical Holdings, Inc., (OTC:CTTH) was granted a patent for an orally administered wafer. Nevertheless the GRANTED patent does support the effectiveness of formulations using THC and CBD to treat Psoriasis, and in the case of OWCP they include a broader scope of skin disorders including Psoriasis.
Here is OWCP's current patent application, UPDATED on February 15, 2018.
CANNABIS-BASED EXTRACTS AND TOPICAL FORMULATIONS FOR USE IN SKIN DISORDERS
https://patentimages.storage.googleapis.com/b8/1c/09/45c55ac2ed6c11/US20180042890A1.pdf
The science in our patent application is very impressive and extensive.
I'm here because I'm a long investor in OWCP and I believe this company will be huge. A lot of false claims are made repetitiously and so I post facts about OWCP.
$OWCP
tick tock
:)
Yes it was... textbook. It wasn't able sustain a continued fall in price though. I guess it didn't trigger many stop losses if any at all. Investors aren't falling for it either.
Float getting locked up tight.
False Claims and noise aren't working either.
Shorting interest will decline, and OWCP pps will continue to rise.
The day news hits OWCP will literally rocket to the moon... well figuratively
$OWCP
tick tock
:)
Then why are you here?
Wow man, you're an expert on everything.
How many pre-clinical studies have you been a part of in Israel?
How many pre-clinical studies have you been a part of ANYWHERE in the world?
Here's a FACT:
OWCP is spending real money with the biggest research hospital in Israel, Sheba Academic Medical Center’s hospital, whom they entered in to 2 collaboration agreements with OWCP to conduct R&D on multiple myeloma, and the psoriasis cream.
Is Sheba in on the scam too?
WRONG! You obviously have NOT read the entire 8-K.
Nevertheless, where in the 8-K does it say your false claim?
I-GLOW wrote:
"this is a toxic loan disguised as a Equity Purchase Agreement - when the discount is floorless - that is by definition a toxic loan.
If it was a loan or investment the company wouldn't be required to file a S-1 so that the convertible stock was free trading immediately."
Section and page number please.
We had a solid 10-Q. On Page 17 it says:
"On April 30, 2018, we entered into and consummated a Securities Purchase Agreement with a new investor, pursuant to which, we issued (i) 500 shares of Preferred Stock designated as Series A Preferred Stock that are convertible into 25,000,000 shares of common stock and (ii) Warrants that are eligible for conversion into 12,500,000 shares of common stock for an aggregate purchase price of $5,000,000. See note 5, Subsequent Events, in our financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Raising of funds mitigates any substantial doubt related to our ability to continue as a going concern."
For a startup R&D company to say that about the "going concern" in a 10-K or 10-Q is an very positive indicator.
"Funding of Our Research Programs
On October 22, 2014, we entered into a collaboration agreement with the Sheba Academic Medical Center’s hospital (“Sheba”) relating to the use of cannabis to treat myeloma. Within the framework of this collaboration agreement, we conducted pre-clinical studies on multiple myeloma, which have commenced in April 2015. Pursuant to this collaboration agreement, we are obligated to pay Sheba $170,000. As of March 31, 2018, we have paid Sheba $65,669 as per Sheba’s payment requests.
In addition, pursuant to another collaboration agreement, we are obliged to pay Sheba $170,000 throughout 2017 and 2018 for conducting the Study for the cream for treatment of psoriasis. As of March 31, 2018, we have paid Sheba $43,066 as per Sheba’s payment requests.
At present, we use our available working capital to fund these studies.
Our expenditures allocated to our corporate activities conducted through our facilities in Ramat Gan were $16,496 for the three months period ended March 31, 2018 and we expect it will be approximately $66,000 for the year ending December 31, 2018."
The fact that Sheba is requesting payment on two different studies per their agreement with OWC means that the studies are happening.
I'm so glad that we have a management team that is focused on the massive gains of doing this right and protecting our IP. Investors want to be informed about the progress more regularly but I want them to focus on the R&D and focus on the patent process, which they are.
Funding in place.
Awesome bio-pharmaceutical R&D Team.
Leadership with lots of patent experience and success.
31 registered patents in 9 Patent Families.
Located in Israel which is by far the front runner of Cannabis Research
OWCP is looking real good.
$OWCP
This post is true!
Well gee wiz you might as well conclude that stock trading is a myth too.
I remember back in the day when we use to do it though.
....those were the days.
LOL...
Not just market makers do it, but yea it happens all the time.
This morning just after opening was a textbook Bear Raid on OWCP.
The writing was on the wall with all the false claims being made in such repetition.
After all that effort, could only keep OWCP's PPS down .015 from yesterday.
Doesn't matter, shorts don't have much more they can do now, and PPS will continue to rise.
Float is locking up, and a run is coming, and there's nothing you can do to stop it.
Now get back to work.
$OWCP
LOL... That's all you got?
We had a Bear Raid right after opening this morning. They heavily coded their trades, it was super obvious.
But now what? They're going to have to cover eventually. No more JF shares, and after a solid 10-Q and $5 Million investment by an Institutional Investor, OWCP shares are getting harder to get at cheap prices. The float is becoming locked.
Lots of folks are watching this stock EVERYDAY... even you :)
$OWCP
...tick tock
In what way? Do you realize the link you posted is from January 2010? Information from the link you posted has absolutely nothing to do with Israeli company OWC or OWCP Stock.
OWCP stock is the ticker symbol for OWC Pharmaceutical Research Corp. and is traded on the OTCQB market.
OWC Pharmaceutical Research Corp. (OWCP), has nothing to do with the US Dept of Labor's Office of Workers’ Compensation Programs (OWCP).
They are 2 completely different entities.
You are posting stuff that has NOTHING TO DO WITH THIS COMPNY and OWCP stock.
Office of Workers’ Compensation Programs (OWCP), has nothing to do with OWCP stock.
The Office of Workers' Compensation Programs is a program in the US Dept of Labor, which administers four major disability compensation programs which provide wage replacement benefits, medical treatment, vocational rehabilitation and other benefits to certain workers or their dependents who experience work-related injury or occupational disease.
OWCP stock is the ticker symbol for OWC Pharmaceutical Research Corp. and is traded on the OTCQB market.
Two different OWCP results on google that have nothing to do with each other.
Nope. JF is gone, he's in the hands of the SEC and they just filed an amended Complaint against him on May 10th.
We have $5 Million invested from an Institutional Investor. With Dr. Hirsch and Dr. Zeevi, we have the right team to make big things happen.
Dr Zeevi is an expert in this kind of R&D and getting patents granted. It's very likely that she read every patent application as well as reviewed all of the work OWCP had done before joining the OWCP team. There's no way she would have joined OWCP if it was not legit.
Dr. Oron Yacoby Zeevi, age 57, Chief Scientific Officer : Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry. In 2008, Dr. Yacoby Zeevi joined Neuroderm Ltd (Nasdaq: NDRM), a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders as the Vice President of Research and was promoted to the position of VP R&D. From October 2016 until her recent departure, she served as Chief Scientific Officer of Neuroderm, which was sold to Mitsubishi Tanabe Pharma for US $1.1 billion in July 2017.
Dr. Yacoby Zeevi, is the inventor of over 50 issued patents and patents pending, Her expertise lies in industry-oriented innovation and scientific research, accelerating and orchestrating the evolution of new ideas through R&D PoC, IP, CMC, early efficacy and safety trials, regulatory affairs and market landscape mapping in fields of unmet medical needs, towards development of commercially viable pharmaceutical or agricultural products. Dr. Yacobi Zeevi earned her PHD in micro biology and immunology from the Ben Gurion University of Be’er Sheva, Israel and also holds a degree of Doctor in Veterinary Medicine from the Hebrew University of Jerusalem
OWCP Patent links (9 patent families, 31 patents, and counting) All are active, zero patents rejected. These patents are being amended to perfection. People that actually know about the patent process know that it's a process.
The science involved with these patent applications is impressive.
OWCP recent Patent update May 3, 2018:
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20180116998.PGNR.&OS=DN/20180116998&RS=DN/20180116998
OWCP recent Patent revision February 15, 2018:
https://patentimages.storage.googleapis.com/8f/73/66/91ea24f64b0281/US20180042845A1.pdf
OWCP recent Patent revision February 15, 2018:
https://patentimages.storage.googleapis.com/b8/1c/09/45c55ac2ed6c11/US20180042890A1.pdf
OWCP recent Patent revision December 28, 2017:
https://patentimages.storage.googleapis.com/2f/aa/58/aa80e19d0880d5/US20170367875A1.pdf
United States Patent and Trademark Office (USPTO) (search from the Patent Application Information Retrieval (PAIR) (patent application # 15536738 and 15629230, and 15708187))
https://www.uspto.gov/patents-application-process/search-patents
World Intellectual Property Organization (simple search One World Cannabis)
https://patentscope.wipo.int/search/en/result.jsf
European Patent Register
https://register.epo.org/smartSearch?searchMode=smart&query=one+world+cannabis
IP Australia
http://pericles.ipaustralia.gov.au/ols/auspat/quickSearch.do?queryString=one+world+cannabis&resultsPerPage=
Canadian Intellectual Property Office
http://www.ic.gc.ca/opic-cipo/cpd/eng/search/results.html?query=one+world+cannabis&start=1&num=50&type=basic_search&newSearch=0
Israel Patent Office (click English in top left, then advance search for applicant One World Cannabis)
http://www.ilpatsearch.justice.gov.il/UI/RequestsList.aspx
OWCP's expert Israeli team delivers years of proven practices in diverse disciplines, including medical science and regulatory affairs, as well as extensive cannabis-related issues experience. They are focused on discovering, developing and commercializing cannabis-based novel therapeutics products and treatments specifically designed for several medical conditions, starting with multiple myeloma, psoriasis, fibromyalgia, PTSD (post-traumatic stress disorder) and migraines.
One World Cannabis aspires to become one of the world’s leading players in the hyper-growing market of medical cannabis by providing the missing yet prerequisite element of scientific validity for cannabis based products.
The Company is committed to and the highest standards of integrity and ethics in proposing, conducting and reporting research. All its investigations and researches are conducted at the facilities of leading Israeli medical centers, as well as at the labs of the R&D pharmaceutical companies we contracted with. The Company adheres to all the necessary regulatory requirements, including submitting its research protocols to Ethics Committee (IRB) approval.
OWCP Presentation 2018 Wall Street Conference
Closed green and up 4% from yesterday. HOD was .27, so yea I missed a bit on my prediction of .30, and we shall see what it does tomorrow. I got a good feeling about it. That was a solid 10-Q. Come Friday I think we will be well above .30
I like the slow and steady climb, but my gut is telling me it's gonna run.... shorts are gonna be caught with their pants down. But that's the game, we'll see :)
Short Data for OWCP
https://www.otcshortreport.com/company/OWCP
If OWCP keeps rising, short squeeze is coming.
$OWCP
Lots of folks watching OWCP right now.
$OWCP
$5 Million investment is mentioned on page 17 of the 10-Q.
"On April 30, 2018, we entered into and consummated a Securities Purchase Agreement with a new investor, pursuant to which, we issued (i) 500 shares of Preferred Stock designated as Series A Preferred Stock that are convertible into 25,000,000 shares of common stock and (ii) Warrants that are eligible for conversion into 12,500,000 shares of common stock for an aggregate purchase price of $5,000,000. See note 5, Subsequent Events, in our financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Raising of funds mitigates any substantial doubt related to our ability to continue as a going concern."
$OWCP
The little snippets that you quoted out of the SEC Complaint against Friedland do NOT state anywhere that "OWCP provided the fraudulent 144 Opinion Letters to have the restrictive legend removed".
You have repeated this false claim again and again.
I-GLOW writes:
"OWCP provided the fraudulent 144 Opinion Letters to have the restrictive legend removed."
Where does it say this in the SEC document? Paragraph and page please.
You obviously have not read the entire 8-K. Did you even read the 8-K/A? It's much shorter.
I am feeling very generous - let me provide some help and guidance.
Item 1.01 Entry into a Material Definitive Agreement.
On April 30, 2018, OWC Pharmaceutical Research Corp. (the “Registrant”) entered into and consummated a Securities Purchase Agreement (the “Agreement”) with a non-US-based institutional investor (the “Purchaser”). Under the terms and conditions of the Agreement, the Registrant sold and the Purchaser bought, (i) 500 shares of the Registrant’s new series of preferred stock designated as Series A Preferred Stock (the “Preferred Shares”), which are currently convertible into 25,000,000 shares of the Registrant’s common stock, par value $0.00001 per share (“Common Stock”) and (ii) Warrants (the “Warrants”) representing the right to acquire 12,500,000 shares of Common Stock (which shall be adjusted in accordance with the terms and conditions set forth in the Certificate of Designations and the Warrants) for an aggregate purchase price of $5,000,000. Newbridge Securities Corporation, through LifeTech Capital, acted as exclusive placement agent for the transaction.
$OWCP
There is no evidence that OWC colluded with Jeffery Friedland in 2014. Jeffery Friedland’s activities in Colorado were his activities, not those of OWC.
Your post reminds me of a previous false claim you made.
I-GLOW wrote:
“Yes, most certainly there was collusion and OWCP was complicit in the share selling scheme from beginning stating in 2014. The scam started at the Friedland dinner party in 2014.”
This statement of yours is no where in the SEC complaint document: “there was collusion and OWCP was complicit in the share selling scheme from beginning stating in 2014”, and does not merit a preface such as “Yes, most certainly”. The SEC action did not state this. It is not fact. It is not “most certainly”. The SEC complaint against Jeffery Friedlant actually exonerates OWC in my opinion, and they are not a party in this SEC action; fact.
There was no representative of OWC at Jeffery Friedland’s dinner party in Colorado in 2014. This was Jefferey Friedland doing his own thing in Colorado and the OWC management in Israel was not party to it.
According to the SEC, concerning OWC’s interaction with Jeffery Friedland in 2014, the FACTS ARE:
"29. In August 2014, Friedland purchased 1,322,222 shares of restricted OWC stock for $119,000 pursuant to a subscription agreement that he signed on behalf of Intiva, and the ownership of these securities was identified in OWC’s SEC filings (albeit with “Invita” rather than Intiva). On or around August 18, 2014, OWC provided an opinion letter to its transfer agent from a disbarred attorney in connection with its issuance of stock to Intiva."
There was nothing fraudulent about OWC issuing 1,322,222 shares of restricted OWC stock to Intiva in August 2014. Since there was nothing wrong with the issuance of these shares, there was nothing indicated as being fraudulent about the opinion letter which OWC provided to its transfer agent.
According to the SEC complaint against Friedland it says “from a disbarred attorney”, but we don’t know any additional information about the attorney OWC used in 2014. He/she may have had a current license to practice law at that time. Wether the attorney was disbarred prior to or after August 2014 is information not given by the SEC.
————————————————————————————————
I-GLOW writes in previous post:
"What part about OWCP providing a Fraudulent Opinion Letter to expedite the removal of the restrictive legend are you ignoring."
Where does it say this in the SEC document? Paragraph and page please.
I'm still waiting. Can you provide just the paragraph number please?
OWCP ....a big run is coming and there's not a damn thing you can do about it :)
LOL... shorts be trippin' ...OWCP steady rise and squeeze is coming.
Short Interest Data for OWCP:
https://www.otcshortreport.com/company/OWCP
$OWCP
BIG RUN COMING
...tick tock
The $5 Million investment by an Institutional Investor was on April 30, 2018 so that will be covered in Q2, because it happened in Q2. This Quarterly report we just got today is for Q1. That's how it works in the corporate world.
And what a great deal this is for OWCP. $5 Million for 25M shares, plus warrant to purchase another 12,500,000 shares for $5 Million.
So it's actually $10 Million for 37,500,000 shares common stock if the Warrants are exercised.
That's a sweet deal!
Sure. Generally speaking, all bio-pharmaceutical R&D stocks are spec stocks. Either on the big boards or OTC, they are spec stocks.
$5 Million investment by an International Investor for 25M shares plus Warrants for another $5 Million for 12,500,00 shares of common stock is a sweet deal.
Funding in place.
Awesome bio-pharmaceutical R&D Team.
Leadership with lots of patent experience and success.
31 registered patents in 9 Patent Families.
Located in Israel which is by far the front runner of Cannabis Research
OWCP is looking real good.
$OWCP
Nope that's not what they did. They cancelled claims 1-87, and then revised the rest of the application. As you have been told by many, the patent process is a process. You obviously have never actually done any work whatsoever with the patent process.
Calling people clowns is all you got...
LOL... I love your desperation :)
OWCP is coming up on a run and there's not a damn thing you can do about it.
$OWCP
...tick tock
The OWCP management and research team are OWCP shareholders themselves.
You confirmed that they revised this patent application and that it is active.
Let's take a closer look indeed... the science behind it is impressive.
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20180116998.PGNR.&OS=DN/20180116998&RS=DN/20180116998
When OWCP does deliver it will mean massive gains for long investors.
We have $5 Million invested from an Institutional Investor, and we have the right team to make big things happen with Dr. Hirsch and Dr. Zeevi.
Dr Zeevi is an expert in this kind of R&D and getting patents granted and it's very likely that she read every patent application as well as reviewed all of the work OWCP had done before joining the OWCP team. There's no way she would have joined OWCP if it was not legit.
Dr. Oron Yacoby Zeevi, age 57, Chief Scientific Officer : Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry. In 2008, Dr. Yacoby Zeevi joined Neuroderm Ltd (Nasdaq: NDRM), a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders as the Vice President of Research and was promoted to the position of VP R&D. From October 2016 until her recent departure, she served as Chief Scientific Officer of Neuroderm, which was sold to Mitsubishi Tanabe Pharma for US $1.1 billion in July 2017.
Dr. Yacoby Zeevi, is the inventor of over 50 issued patents and patents pending, Her expertise lies in industry-oriented innovation and scientific research, accelerating and orchestrating the evolution of new ideas through R&D PoC, IP, CMC, early efficacy and safety trials, regulatory affairs and market landscape mapping in fields of unmet medical needs, towards development of commercially viable pharmaceutical or agricultural products. Dr. Yacobi Zeevi earned her PHD in micro biology and immunology from the Ben Gurion University of Be’er Sheva, Israel and also holds a degree of Doctor in Veterinary Medicine from the Hebrew University of Jerusalem
As for the drop in the PPS, everyone knows that this stock took a big hit from the JF case, but that snake in the grass is gone now and shorts aren't going to be able to cover, which will likely mean that naked short interest will decline. Much like "Equity Short Interest" drastically declined right after JF sold the last of his shares.
This stock is going to blast off soon. It got to .27 today, I predict over .30 tomorrow :)
$OWCP
....going to be HUGE!!!!!!!
tick tock
OWCP recent Patent update May 3, 2018:
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20180116998.PGNR.&OS=DN/20180116998&RS=DN/20180116998
OWCP recent Patent revision February 15, 2018.
https://patentimages.storage.googleapis.com/8f/73/66/91ea24f64b0281/US20180042845A1.pdf
OWCP recent Patent revision February 15, 2018.
https://patentimages.storage.googleapis.com/b8/1c/09/45c55ac2ed6c11/US20180042890A1.pdf
OWCP recent Patent revision December 28, 2017.
https://patentimages.storage.googleapis.com/2f/aa/58/aa80e19d0880d5/US20170367875A1.pdf
United States Patent and Trademark Office (USPTO) (search from the Patent Application Information Retrieval (PAIR) (patent application # 15536738 and 15629230, and 15708187))
https://www.uspto.gov/patents-application-process/search-patents
World Intellectual Property Organization (simple search One World Cannabis)
https://patentscope.wipo.int/search/en/result.jsf
European Patent Register
https://register.epo.org/smartSearch?searchMode=smart&query=one+world+cannabis
IP Australia
http://pericles.ipaustralia.gov.au/ols/auspat/quickSearch.do?queryString=one+world+cannabis&resultsPerPage=
Canadian Intellectual Property Office
http://www.ic.gc.ca/opic-cipo/cpd/eng/search/results.html?query=one+world+cannabis&start=1&num=50&type=basic_search&newSearch=0
Israel Patent Office (click English in top left, then advance search for applicant One World Cannabis)
http://www.ilpatsearch.justice.gov.il/UI/RequestsList.aspx
$OWCP
I don't think you're actually holding any shares but whatever, doesn't matter.
My point is that you said "there is absolutely nothing being accomplished"
The fact is you are WRONG!
Jimbudget wrote:
"I agree. The problem is there is absolutely nothing being accomplished."
How about use your eyes:
If you own shares of OWCP how about do a little DD instead of saying ridiculous negatives about the company?
Jimbudget wrote:
"I agree. The problem is there is absolutely nothing being accomplished."
Use your eyes:
OWCP recent update May 3, 2018:
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20180116998.PGNR.&OS=DN/20180116998&RS=DN/20180116998
OWCP recent revisions February 2018.
https://patentimages.storage.googleapis.com/8f/73/66/91ea24f64b0281/US20180042845A1.pdf
https://patentimages.storage.googleapis.com/2f/aa/58/aa80e19d0880d5/US20170367875A1.pdf
https://patentimages.storage.googleapis.com/b8/1c/09/45c55ac2ed6c11/US20180042890A1.pdf
The science involved with these patent applications is impressive.
There is definitely much being accomplished by our OWCP team.
$OWCP ...going to be huge for patient investors.
Why you calling me a ho. I just want to trade stocks. Is JBZY a buy or not?
WRONG! You're repeating the same false claims.
I-GLOW writes:
"LMAO!!! There it is - OWCP provided a fraudulent 144 Opinion Letter from a Disbarred attorney."
Where does it say that OWC provided a fraudulent opinion letter anywhere in the SEC Complaint against Jeffrey Friedland? Paragraph and page number please.
why don't ya?
Yesterday JBZY hit 1.00, like I said before, if this goes below .80 I might be a buyer.
Did the fins ever come out?
Historical short data for OWCP.
https://www.otcshortreport.com/company/OWCP
OWC is an Israeli company. Israel is the front runner of cannabis research. THC was discovered in Israel.
Israeli scientist Dr. Raphael Mechoulam, was the first to identified CBD’s stereochemistry in his laboratory at the Hebrew University of Jerusalem back in 1963. Mechoulam also was the first to identify the structure of THC in 1964, and is more or less considered the godfather of modern cannabis.
Mechoulam coined the term “cannabinoids” and he has elucidated various other chemical compounds, or “cannabinoids”, occurring in both the cannabis plant and the human body.
https://daggacouple.co.za/1964/08/27/the-discovery-of-thc-israel-1964/
OWCP's expert Israeli team delivers years of proven practices in diverse disciplines, including medical science and regulatory affairs, as well as extensive cannabis-related issues experience. They are focused on discovering, developing and commercializing cannabis-based novel therapeutics products and treatments specifically designed for several medical conditions, starting with multiple myeloma, psoriasis, fibromyalgia, PTSD (post-traumatic stress disorder) and migraines.
One World Cannabis aspires to become one of the world’s leading players in the hyper-growing market of medical cannabis by providing the missing yet prerequisite element of scientific validity for cannabis based products.
The Company is committed to and the highest standards of integrity and ethics in proposing, conducting and reporting research. All its investigations and researches are conducted at the facilities of leading Israeli medical centers, as well as at the labs of the R&D pharmaceutical companies we contracted with. The Company adheres to all the necessary regulatory requirements, including submitting its research protocols to Ethics Committee (IRB) approval.
OWCP Presentation 2018 Wall Street Conference